Protagonist Therapeutics, Inc. · NASDAQ:PTGX
Protagonist Therapeutics — Corporate Update (November 2018)
7 slides from Protagonist Therapeutics's corporate update, Nov 27, 2018
Slide 1: Cautionary Note on Forward-Looking Statements
Cautionary Note on Forward-Looking Statements 2 This presentation contains forward - looking statements for purposes of the safe harbor provisions of the Private Securi ties Litigation Reform Act of 1995. Forward - looking statements include statements regarding our intentions or current expectation
Slide 2: PN-10943: Oral, GI-Restricted a4b7-Integrin Antagonist Summary
PN-10943: Oral, GI-Restricted a4b7-Integrin Antagonist Standard backup approach to manage risk with the front-runner PN-10943 in comparison to PTG-100 In vitro potency: 5.5 fold more potent in T cell adhesion assay 2.6 fold slower off-rate and therefore longer binding lifetime Target engagement: Sim
Slide 3: PN-10943: More Potent Than PTG-100
PN-10943: More Potent Than PTG-100 Cell Adhesion or Surface Plasmon Resonance Binding Assays Integrin 47 41 Ligand MAdCAM-1 (IC50 nM) VCAM-1 (IC50 nM) PTG-100 1.5 > 100,000 (> 67,000-fold) PN-10943 0.27 > 12,000 (> 44,000-fold) 5.5-fold more potent in blocking human T cell adhesion assay with simila
Slide 4: Similar RO% and T Cell Trafficking at Lower Doses
PN-10943: Similar RO% and T Cell Trafficking at Lower Doses 15 Day DSS Colitis Mouse Model Circulating Cell Numbers CD4+ Effector Memory T cells 5 Receptor Occupancy CD4+ Effector Memory T cells V e h i c l e P T G - 1 0 0 , 5 5 m p k / d P N - 9 4 3 A , 5 5 m p k / d P N - 9 4 3 A , 1 8 m p k / d 0
Slide 5: More Efficacious than PTG-100
PN-10943: More Efficacious than PTG-100 9 Day TNBS Colitis Rat Study Colon weight/length 6 Histopathology Preserving Colon Tissue Integrity Sham Vehicle PTG-100 81 mpk/d PN-10943 79 mpk/d 0 200 400 600 800 C o l o n W e i g h t / L e n g t h ( m g / c m ) **** * *** Sham Vehicle PTG-100 81 mpk/d PN-
Slide 6: Milestones Through 2020
2018 2019 2020 Q4 1H 2H 1H 2H PN-10943 Ph1 trial initiation PTG-300 Ph2 b-Thal initiation PN-10943 Ph1 PD readouts PTG-300 Ph2 2nd indication initiation PTG-200 (Janssen partnership) US IND filing for Ph2A Crohn’s initiation PN-10943 Ph2A UC initiation PTG-300 Ph2 b-Thal initial readout PTG-300 Ph2
Slide 7: Milestones Through 2020
Milestones Through 2020 Cash Runway through End of 2020 Q4 1H 2H 1H 2H + PN-10943 Ph1 + PN-10943 Ph1 + PN-10943 Ph2A = + PTG-300 Ph2 2° PTG-300 -Thal trial initiation PD readouts UC initiation indication initial topline results readout + PTG-300 Ph2B- + PTG-300 Ph2 24 + PTG-300 Ph2 p- Thal initiatio
Protagonist Therapeutics — Corporate Update (November 2018) on 6ix